Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This protocol provides access to investigational convalescent plasma for hospitalized
patients with COVID-19. Following provision of informed consent, patients will be
administered around 500 mL of convalescent plasma obtained from an individual who has
recovered from a documented SARS-CoV-2 infection. The study aims to evaluate the efficacy and
safety of anti-SARS-CoV-2 convalescent plasma as adjunctive therapy in preventing disease
progression (prevention of ICU admission) among hospitalized patients with COVID-19. Safety
outcomes include serious adverse events judged to be related to convalescent plasma. Other
information which will be collected includes patient demographics and clinical data which
includes quick SOFA scores, ventilator-free days, ICU-free days, dialysis-free days and
28-day mortality.